The Benefit of Sirolimus Maintenance Immunosuppression and Rabbit Antithymocyte Globulin Induction in Liver Transplant Recipients That Develop Acute Kidney Injury in the Early Postoperative Period

Table 2

Overall secondary endpoints.

	Tacrolimus ()	Sirolimus ()
Progression to RRT, (%)	0	0
Biopsy-proven acute cellular rejection, (%)	24 (14)^b	10 (34)^b
Graft survival 1 year after transplant, %	90.7^c	82.6^c
Patient survival 1 year after transplant, %	95.6^b,c	84.8^b,c

Outlier detected using Grubb’s test.
between treatment groups.
^cSurvival analysis: for tacrolimus group and for sirolimus group.